Profile data is unavailable for this security.
About the company
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
- Revenue in CHF (TTM)59.76bn
- Net income in CHF14.02bn
- LocationRoche Holding AGGrenzacherstr. 124BASEL 4058SwitzerlandCHE
- Phone+41 9 732354295
Mergers & acquisitions
|Acquired company||Deal status||Date||Date /|
|ROG:SWX since |
|GenMark Diagnostics Inc||Deal completed||15 Mar 2021||15 Mar 2021Deal completed||11.38%||1.84bn|
|Enterprise Therapeutics Ltd||Deal completed||07 Oct 2020||07 Oct 2020Deal completed||7.12%||96.58m|
|Inflazome Ltd||Deal completed||21 Sep 2020||21 Sep 2020Deal completed||-1.15%||449.81m|